Evolent Health Reports Q1 2026 Results; Revenue Up, Net Loss Narrowed

Evolent Health, Inc.

2026-Q1 EPS reported -$0.24 revenue$496,246,000

Revenue $496.2M vs $483.6M in Q1 2025; net loss improved to $26.6M from $72.3M.
Adjusted EBITDA $22.1M with margin 4.4%, down from $36.9M margin 7.6% prior year.
Signed new revenue agreements: advanced imaging solution for ~4.5M lives; oncology/cardiology expansion expected >$200M annual revenue.
CEO Seth Blackley highlighted successful oncology launches at Highmark and Aetna, focus on AI opportunity.
Medical expense ratio rose to 93.3% from 68% (84% excluding Evolent Care Partners).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. reported quarter ended March 31, 2026 results: revenue $496,246, net income $(26,632).

Period: quarter ended March 31, 2026
Revenue: $496,246
Net income: $(26,632)
Result: reported results

Exact text from the filing

March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case): For the Three Months Ended March 31, 2026 2025 Financial Results: Revenue $ 496,246 $ 483,649 Net loss attributable to common shareholders of Evolent Health, Inc. $ (26,632) $ (72,250) Net loss margin (5.4) % (14.9) % Adjusted EBITDA $ 22,067 $ 36,860 Adjusted

View on SEC.gov

Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-26-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.